NCT05411094

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

SUSPENDEDPHASE1INTERVENTIONAL

Trial Details

Start: 2023-05-22Est. Completion: 2026-07-01

Enrollment target: 18 participants

Locations

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
Los Angeles General Medical Center, Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
University of Michigan - Brighton Center for Specialty Care, Brighton, Michigan, United States
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin, United States
University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

Digestive System Malignancies

Digestive system malignancies are among the most common types of cancers in China, primarily including esophageal cancer…

Tianjin, ChinaEst. completion Jan 30, 2026

Resectable Pancreatic Ductal AdenocarcinomaBorderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic c…

Seattle, United StatesEst. completion Jul 14, 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.